Comments
Aurobindo Pharma Ltd is has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Tamsulosin Hydrochloride Capsules and Clindamycin Palmitate Hydrochloride for Oral Solution.
Tamsulosin Hydrochloride Capsule is the generic equivalent of Boehringer Ingelheim Pharmaceuticals’ Flomax Capsules and is indicated for the treatment of symptoms of an enlarged prostate (Benign Prostatic Hyperplasia - BPH) in men.
The market size of the product is estimated to be $244 million for the 12 months ending September 2012, according to IMS.
Clindamycin Palmitate Hydrochloride for Oral Solution is the generic equivalent of Pharmacia & Upjohn’s Cleocin Pediatric. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria in infants.
The market size of the product is estimated to be $57 million for the 12 months ending September 2012, according to IMS.
The products would be launched soon, the Hyderabad-based company said in a release on Saturday.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.